- The following is an archived discussion of the DYK nomination of the article below. Please do not modify this page. Subsequent comments should be made on the appropriate discussion page (such as this nomination's talk page, the article's talk page or Wikipedia talk:Did you know), unless there is consensus to re-open the discussion at this page. No further edits should be made to this page.
The result was: promoted by Cwmhiraeth (talk) 05:49, 1 September 2018 (UTC)
| DYK toolbox |
|---|
MIS416
edit... that a drug derived from bacteria that cause acne is being studied to treat multiple sclerosis and cancer?"Propionibacterium acnes is a major inhabitant of adult human skin, where it resides within sebaceous follicles, usually as a harmless commensal although it has been implicated in acne vulgaris formation." [1] "Propionibacterium acnes was modified using biochemical extraction methods generating a suspension of microparticles (MIS416)"[2] "23 Mar 2018 Preclinical development for cancer is ongoing in New Zealand; 23 Mar 2018 Discontinued - Phase-II for Multiple sclerosis in New Zealand, Australia (IV)"[3]- ALT1:... that ...?
- Reviewed: Haven't submitted 5 DYKs
Created/expanded by Natureium (talk). Self-nominated at 01:47, 15 August 2018 (UTC).
Article is long enough and new enough. No copyright or plagiarism concerns. Sources are reliable. Hook is interesting, but my opinion would be to include the name of the drug and put links around multiple sclerosis and cancer. QPQ does not apply. No picture is used.--LittleT889 (talk) 14:40, 19 August 2018 (UTC)
Hi, I came by to promote this, but first formatted the refs, added a ref, and edited the article. I'm not sure that we should post this rosy hook on the main page because the drug seriously failed its second clinical trial. The real story so far is the insider trading charges against the US Congressman, which we can't put on the main page due to BLP issues. Perhaps a better hook would talk about its compassionate use in New Zealand even before clinical trials began. Yoninah (talk) 23:25, 29 August 2018 (UTC)
- ALT1: ... that MIS416, a drug derived from bacteria that cause acne, was used to treat multiple sclerosis in New Zealand under a compassionate use law before clinical trials were unable to prove its efficacy?
- Would this be better? Natureium (talk) 23:56, 29 August 2018 (UTC)
@Natureium: Yes, thank you. But where does it say this in the citation provided? The reference only takes you to the name of a paper. Could you refine the citation? I tweaked the hook to name the drug, as the previous reviewer also requested. Yoninah (talk) 00:30, 30 August 2018 (UTC)
Oh, I see it's offline. No problem. Offline ALT1 hook ref AGF and cited inline. Rest of review per LittleT889. ALT1 good to go. Yoninah (talk) 00:33, 30 August 2018 (UTC)- Sorry, I must have copied the link badly. The paper says "MIS416 was initially used in patients with SPMS outside of a formal clinical trial setting under compassionate use legislation in New Zealand." In case it's not clear, SPMS refers to secondary progressive multiple sclerosis. Natureium (talk) 00:35, 30 August 2018 (UTC)
